Search hospitals > South Dakota > Aberdeen
Avera Cancer Institute-Aberdeen
Claim this profileAberdeen, South Dakota 57401
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Colorectal Cancer
Conducts research for Adenocarcinoma
57 reported clinical trials
10 medical researchers
Summary
Avera Cancer Institute-Aberdeen is a medical facility located in Aberdeen, South Dakota. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Adenocarcinoma and other specialties. Avera Cancer Institute-Aberdeen is involved with conducting 57 clinical trials across 124 conditions. There are 10 research doctors associated with this hospital, such as Benjamin M. Solomon, David Starks, Heidi McKean, and William C. Spanos.Area of expertise
1Cancer
Global LeaderStage IV
HER2 positive
ER positive
2Breast Cancer
Global LeaderER positive
HER2 negative
PR positive
Top PIs
Benjamin M. SolomonAvera Cancer Institute4 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Cancer
25 reported clinical trials
44 drugs studied
David StarksAvera Cancer Institute5 years of reported clinical research
Studies Ovarian Cancer
Studies Endometrial Cancer
18 reported clinical trials
32 drugs studied
Heidi McKeanAvera Cancer Institute1 year of reported clinical research
Studies Colorectal Cancer
Studies Tumors
9 reported clinical trials
23 drugs studied
William C. SpanosAvera Cancer Institute2 years of reported clinical research
Studies Cancer
Studies Oropharyngeal Cancer
5 reported clinical trials
13 drugs studied
Clinical Trials running at Avera Cancer Institute-Aberdeen
Breast Cancer
Pancreatic Cancer
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Pancreatic Carcinoma
Esophageal Cancer
Colorectal Cancer
Adenocarcinoma
Non-Small Cell Lung Cancer
Esophageal Adenocarcinoma
Giredestrant vs. Fulvestrant
for Advanced Breast Cancer
This trial is testing two drug combinations to treat a specific type of advanced breast cancer that no longer responds to standard hormone treatments. The goal is to see which combination works better by stopping the cancer cells from growing.
Recruiting2 awards Phase 38 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Avera Cancer Institute-Aberdeen?
Avera Cancer Institute-Aberdeen is a medical facility located in Aberdeen, South Dakota. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Adenocarcinoma and other specialties. Avera Cancer Institute-Aberdeen is involved with conducting 57 clinical trials across 124 conditions. There are 10 research doctors associated with this hospital, such as Benjamin M. Solomon, David Starks, Heidi McKean, and William C. Spanos.